title: Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache.
abstract: In lumbar cerebrospinal fluid (CSF) obtained from patients with chronic tension-type headache (CTH), the concentrations of beta-endorphin, met-enkephalin, dynorphin, cholecystokinin (CCK), calcitonin gene-related peptide (CGRP), and somatostatin were measured before and after 8 weeks of treatment with sulpiride or paroxetine. We previously reported higher than normal met-enkephalin concentrations in CTH. The present study reveals normal basal concentrations of CCK, CGRP and somatostatin and slightly decreased dynorphin in the same patients. Treatment with sulpiride or paroxetine did not change the concentration of any of the neuropeptides measured. These data suggest central changes in opioid systems but not in other peptide systems (CCK, CGRP, somatostatin) involved in nociceptive processing at the level of the spinal cord dorsal horn/nucleus caudalis of the trigeminal nerve in CTH. Such central changes might be pathophysiologically important or merely secondary to other more important occurrences. The lack of changes in neuropeptide concentrations during drug treatment makes planning of studies involving CSF analysis easier, but also limits the probability of obtaining information on specific neuropeptide systems through CSF analysis.
authors.affiliation: Department of Neurology, Gentofte Hospital, Denmark.
authors.forename: F W
authors.initials: FW
authors.lastname: Bach
authors.forename: M
authors.initials: M
authors.lastname: Langemark
authors.forename: R
authors.initials: R
authors.lastname: Ekman
authors.forename: J F
authors.initials: JF
authors.lastname: Rehfeld
authors.forename: S
authors.initials: S
authors.lastname: Schifter
authors.forename: J
authors.initials: J
authors.lastname: Olesen
mesh_terms: D000328:Adult; D000368:Aged; D001481:Basal Metabolism; D015740:Calcitonin Gene-Related Peptide / Q000134:cerebrospinal fluid; D002766:Cholecystokinin / Q000134:cerebrospinal fluid; D002908:Chronic Disease; D065127:Dopamine D2 Receptor Antagonists; D004399:Dynorphins / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009479:Neuropeptides / Q000134:cerebrospinal fluid*; D017374:Paroxetine / Q000494:pharmacology*; D013004:Somatostatin / Q000134:cerebrospinal fluid; D013469:Sulpiride / Q000494:pharmacology*; D018781:Tension-Type Headache / Q000134:cerebrospinal fluid / Q000188:drug therapy*
chemical_list: D065127:Dopamine D2 Receptor Antagonists; D009479:Neuropeptides; D017374:Paroxetine; D013004:Somatostatin; D004399:Dynorphins; D013469:Sulpiride; D002766:Cholecystokinin; D015740:Calcitonin Gene-Related Peptide